KRN-5500 / Biodexa Pharma - LARVOL DELTA

Dara reports year-end 2012 financial results (Marketwire) - "DARA is currently pursuing partnering opportunities for the development and commercialization of KRN5500."

Anticipated licensing / partnership • Pain

Study Results for DARA Biosciences' Lead Drug for Neuropathic Pain, KRN5500, Selected for Presentation by the International Conference on Accelerating the Development of Enhanced Pain Treatments ("ADEPT") (GlobeNewswire) - KRN5500 P2 study to be presented at its Mar 25-26, 2011 conference; Presentation will explore the ramifications of placebo response in randomized, controlled trials for analgesia;

Anticipated P2 data presentation • Pain

Dara BioSciences selected to present the positive results of KRN5500 phase 2 study at the 5th Annual Therapeutics Summit (Globe Newswire) - Dara announced that company has been selected to present positive clinical data results for KRN5500, its lead compound for neuropathic pain, at the 5th Annual Therapeutics Summit to be held Sep 20-21, 2011 in San Francisco

Anticipated P2 data presentation • Pain

DARA BioSciences receives Fast Track Designation from the US FDA for KRN5500 for the treatment of chemotherapy-induced neuropathic pain in patients with cancer (PRNewswire) - This process permits DARA to submit, and the FDA to review, sections of the NDA in advance of DARA's completing entire submission for marketing approval

Fast track designation • Pain